pcDNA3.3_SARS2_omicron_BA.1 Citations (7)
Originally described in: Broadly neutralizing antibodies target the coronavirus fusion peptide.Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW, Kosik I, Hu Z, Zhao M, Mohan D, Cooper AJR, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Drawbaugh D, Eaton B, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Holbrook MR, Nemazee D, Mascola JR, Wilson IA, Tan J Science. 2022 Jul 12:eabq3773. doi: 10.1126/science.abq3773. PubMed Journal
Articles Citing pcDNA3.3_SARS2_omicron_BA.1
| Articles |
|---|
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.
Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J.
Cell Host Microbe. 2022 Nov 4. pii: S1931-3128(22)00523-6. doi: 10.1016/j.chom.2022.10.010.
PubMed
Associated Plasmids |
| microRNA-185 Inhibits SARS-CoV-2 Infection through the Modulation of the Host's Lipid Microenvironment. Ahmed N, Francis ME, Ahmed N, Kelvin AA, Pezacki JP. Viruses. 2023 Sep 14;15(9):1921. doi: 10.3390/v15091921. PubMed |
| Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2. Connor RI, Sakharkar M, Rappazzo CG, Kaku CI, Curtis NC, Shin S, Wieland-Alter WF, Weiner JA, Ackerman ME, Walker LM, Lee J, Wright PF. bioRxiv [Preprint]. 2023 Sep 20:2023.09.19.558444. doi: 10.1101/2023.09.19.558444. PubMed |
| Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2. Connor RI, Sakharkar M, Rappazzo CG, Kaku CI, Curtis NC, Shin S, Wieland-Alter WF, Wentworth J, Mielcarz DW, Weiner JA, Ackerman ME, Walker LM, Lee J, Wright PF. Pathog Immun. 2024 Jun 18;9(2):1-24. doi: 10.20411/pai.v9i2.679. eCollection 2024. PubMed |
| Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection. Vanova V, Nahlikova J, Lickova M, Slavikova M, Kajanova I, Lukacikova L, Sabo M, Radikova Z, Pastorekova S, Klempa B. Viruses. 2025 May 6;17(5):675. doi: 10.3390/v17050675. PubMed |
| Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist. Gonzales J, Young T, Choi H, Park M, Jewel Y, Fan C, Purohit R, Bjorkman PJ, Williams JC. Commun Biol. 2025 Oct 6;8(1):1428. doi: 10.1038/s42003-025-08819-w. PubMed |
| Evolution of the SARS-CoV-2 spike protein in utilizing host transmembrane serine proteases. Milewska A, Cofas-Vargas LF, Poma AB, Pyrc K. iScience. 2025 Aug 6;28(9):113318. doi: 10.1016/j.isci.2025.113318. eCollection 2025 Sep 19. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.